- Research article
- Open Access
- Open Peer Review
Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901
BMC Cancer volume 17, Article number: 121 (2017)
Dispersal of glioblastoma (GBM) cells leads to recurrence and poor prognosis. Accordingly, molecular pathways involved in dispersal are potential therapeutic targets. The mitogen activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway is commonly dysregulated in GBM, and targeting this pathway with MEK inhibitors has proven effective in controlling tumor growth. Since this pathway also regulates ECM remodeling and actin organization − processes crucial to cell adhesion, substrate attachment, and cell motility – the aim of this study was to determine whether inhibiting this pathway could also impede dispersal.
A variety of methods were used to quantify the effects of the MEK inhibitor, PD0325901, on potential regulators of dispersal. Cohesion, stiffness and viscosity were quantified using a method based on ellipsoid relaxation after removal of a deforming external force. Attachment strength, cell motility, spheroid dispersal velocity, and 3D growth rate were quantified using previously described methods.
We show that PD0325901 significantly increases aggregate cohesion, stiffness, and viscosity but only when tumor cells have access to high concentrations of fibronectin. Treatment also results in reorganization of actin from cortical into stress fibers, in both 2D and 3D culture. Moreover, drug treatment localized pFAK at sites of cell-substratum adhesion. Collectively, these changes resulted in increased strength of substrate attachment and decreased motility, a decrease in aggregate dispersal velocity, and in a marked decrease in growth rate of both 2D and 3D cultures.
Inhibition of the MAPK/ERK pathway by PD0325901 may be an effective therapy for reducing dispersal and growth of GBM cells.
Early and continuing dispersal of tumor cells from the primary mass renders GBM refractory to complete surgical excision or targeted chemotherapy and directly leads to recurrence and dismal prognosis. Strategies aimed at containing the primary or recurrent tumor could significantly improve targeted delivery of chemotherapeutic agents and increase the likelihood of total surgical resection. To disperse, cells must first detach from the primary mass, a process that likely involves mechanisms that decrease cohesion between tumor cells . Cells must also attach to substrates at strengths that optimize their motility and secrete factors to facilitate their interaction with parenchyma [2, 3]. In addition, tumor cells must also become relatively compliant so as to deform and “squeeze” through pores in a meshwork of ECM components , and in the case of GBM, astrocytes within the normal brain parenchyma. Accordingly, strategies aimed at preventing tumor cell detachment, limiting motility, and inhibiting changes in compliance offer an effective approach to reduce dispersal. Ideally, such strategies should employ pharmacological agents that can cross the blood–brain barrier and that specifically target molecular pathways involved in mediating cohesion, adhesion, and compliance.
Cadherins, integrins and the extracellular matrix (ECM) are potential therapeutic targets, and various studies have identified drugs that can modulate their expression or function. For example, gamma-linolenic acid (GLA) up-regulates E-cadherin expression and inhibits invasion of lung, colon, breast, melanoma, and liver cancer . Invasion suppression here was likely due to an increase in the strength of intercellular cohesion mediated by up-regulation of E-cadherin. 5-aza-deoxycitidine (5 AC) has also been shown to effectively inhibit invasion by up-regulating E-cadherin expression . Because the down-regulation of E-cadherin is often associated with up-regulation of N-cadherin during epithelial-mesenchymal transition, drugs that can block N-cadherin expression have also been shown to be effective in blocking invasion. Biflorin, a novel o-naphtoquinone, has been shown to inhibit expression of N-cadherin and to block invasion of breast cancer cells . Such drugs could be of potential benefit for glioblastoma given the correlation between increased N-cadherin expression in high-grade gliomas and tissue invasion . Various integrins, including αvβ3 and αvβ5 have also been targets of anticancer therapy. Cilengitide, a cyclic pentapeptide, is a specific inhibitor of these integrins and has been shown to have anti-invasive activity in various glioma models . Given the complexity and heterogeneity of the ECM, and the likelihood that glioma cells tune their integrin receptor fingerprint to match the local ECM microenvironment, drugs that modulate the ECM may prove effective in reducing dispersal. Many of these drugs, including various corticosteroids, target the ECM as a by-product of the drugs’ principal actions. Consequently, this activity may in part be beneficial to the drugs’ disease-modifying properties . An example of such a drug is Dexamethasone (Dex). Dex is currently used to treat brain tumor-related edema associated with mass effect from Glioblastoma . A by-product of the effects of Dex in glioblastoma is its ability to restore fibronectin matrix assembly (FNMA) and decrease detachment of tumor cells from cultured 3D spheroids . However, due to the relatively high doses required, Dex has many side-effects, often limiting its long-term use. Identification of other drugs that can have similar effects but more specifically target pathways involved in modulating integrins and the ECM could be of therapeutic value.
The MAPK/ERK pathway has been identified as a commonly dysregulated pathway in several cancers, most notably in melanoma. Combined targeting of this pathway can have a synergistic effect in controlling tumor growth . Clinical trials using various MEK inhibitors, such as trametinib [13, 14], cobimetinib  and CI 1040 (PD184352)  have been shown to shrink some melanomas, specifically those with BRAF mutations. The MEK inhibitor PD0325901 has also demonstrated efficacy in melanoma cell lines independent of BRAF status . Experimental models have demonstrated in vitro and in vivo efficacy of PD0325901 in controlling tumor growth in animal models of GBM , although studies have identified possible issues with limited access through the blood–brain barrier . To our knowledge, there is only one ongoing phase-2 trial testing the effects of PD0325901 on tumor growth in patients with neurofibromatosis type −1 (NF1) or plexiform neurofibromas  NCT02096471), and none testing efficacy in GBM. The majority of these studies have focused mainly on inhibition of growth and on activation of apoptosis. Inasmuch as MEK inhibitors target pathways that can also influence actin organization and remodeling of the ECM, we asked whether PD0325901 could also serve to impact mechanisms that regulate dispersal of primary human GBM cells.
We first determined whether primary human GBM cells used in this study are sensitive to PD0325901. We then assessed the effects of MEK inhibition on integrin activation vis à vis restoration of FNMA and actin organization in both 2D and 3D cultures. We also quantified the effects of PD0325901 on spheroid mechanical properties including cohesion, stiffness and viscosity. We evaluated effects of PD0325901 in regulating the strength of cell-substrate adhesion, cell motility, dispersal of tumor cells from spheroids, and in an ex vivo dispersal assay. Finally, we determined whether PD0325901 could also influence the growth rate of both 2D and 3D cultures of GBM.
Cell lines, maintenance, treatment, and generation of 3D spheroids
Four human primary glioblastoma cell lines (GBM-1, GBM-2, GBM-3 and GBM-4) were previously isolated and characterized . Samples were examined by a neuropathologist and stained for several markers to confirm their designation as human GBM. Microscopically, all lines were described as astrocytic neoplasms with moderate to high pleiomorphism, vascular endothelial hyperplasia, with areas of abundant necrosis. Lines are all GFAP positive. GBM-1 and GBM-4 exhibit PTEN loss and all lines appear to express p-AKT. All lines express Nestin and BMI-1, both markers of undifferentiated cells. Collectively, pathologic and molecular analysis confirms highly undifferentiated grade IV glioma/glioblastoma. Cells were maintained in Eagles’ Minimal Essential Medium (EMEM)/10% fetal calf serum (FCS) and antibiotics/antimycotics. They were sub-cultured using standard protocols and used at 3rd to 6th passage. Normal human astrocytes (NHA) were purchased from Lonza (Allendale, NJ) and maintained in AGM™ Astrocyte Growth Medium as recommended by the manufacturer. Where required, cells were treated with PD 0325901, a powerful inhibitor of ERK1/2 phosphorylation, at a final concentration of 1 μM w/v DMSO for 24 h prior to assay. Spheroids were generated as previously described .
Immunoblot and immunofluorescence assays
To confirm that PD0325901 inhibited ERK1/2 phosphorylation, cells were treated with either dimethyl sulfoxide (DMSO, vehicle control) or 1 μM PD0325901 overnight under standard tissue culture conditions. Twenty μg of protein was separated by SDS-PAGE under reducing conditions. Gels were blotted to PVDF and probed with anti-phospho P44/42 MAPK or P44/42 MAPK antibodies (Cell Signaling Technologies, Danvers, MA) and appropriate HRP-conjugated secondary antibodies. Blots were developed using Amersham ECL Prime Western Blotting Detection reagent (GE Healthcare Life Sciences, Pittsburgh, PA) and a C-Digit Blot Scanner (Li-COR, Lincoln, NE). Assessment of FNMA, phospho-FAK and actin expression by GBM cells in conventional 2D culture was performed as previously described . For assessment of actin organization in 3D spheroids, aggregates of GBM cells were fixed and permeabilized with 4% paraformaldehyde/0.5% Triton X-100 and incubated in 6nM rhodamine-phalloidin for 30 min. Aggregates were washed 4x with PBS, mounted onto slides, and imaged using a Zeiss AxioImager Z1 spinning disc confocal microscope attached to a Photometrics Evolve 512 EMCCD camera with Metamorph Premier imaging software.
Measurement of aggregate cohesion and viscoelasticity
Aggregate cohesion was measured by tissue surface tensiometry (TST). TST employs a custom-built instrument to compress spherical cellular aggregates between poly-HEMA coated parallel plates to which they cannot adhere. Measurements of aggregate geometry and resistance to the applied force are then applied to the Young-Laplace equation to calculate aggregate surface tension. The method has been described in detail [1, 22–24]. TST measurements are only valid when tissues behave like liquid systems [22–24]. Accordingly, the calculated surface tension of a liquid aggregate, when subjected to two successive compressions (σ1 and σ2), the second greater than the first, will remain constant. In such aggregates the ratio of σ2/σ1 will approach 1 and will be less than the ratio of the force applied at each successive compression (F2/F1). The surface tension of liquid aggregates will also be independent of aggregate size. Only measurements in which surface tension is independent of the applied force and size were used to calculate average σ for each cell line.
For measurement of viscoelasticity, aggregates ranging in size from 200-400 μm were loaded into the tensiometer and subjected to a compressive force for 30 s, whereupon the force was removed and aggregates were allowed to relax for 2 min. A high-speed camera captured 12 frames/s and the shape of the relaxing aggregates was extracted and analyzed using an in-house edge detection and analysis algorithm. Mechanical parameters were extracted from the shape dynamics with a continuum-based model which includes a Kelvin-Voigt bulk enclosed in a stressed surface. This advanced model is different than the simple spring-dashpot or compartmental models previously described . Analysis of the relaxation dynamics was greatly facilitated by a closed-form, analytical solution that we derived. Details of the theory and the data analysis method, as well as preliminary data validating our approach are presented in Additional file 1.
Measurement of shear-flow induced detachment
Cell-ECM attachment was measured by subjecting adhering cells to flow-induced shear stress as previously described . Briefly, DMSO or PD0325901-treated GBM cells were plated at a concentration of 5x104 cells/ml onto 6-well polyethylene terephthalate cell culture inserts (Franklin Lakes, NJ) for 2 h and were then inverted into complete medium and incubated overnight. Inserts were then loaded into custom-designed flow chambers and subjected to 30 dynes/cm of shear stress for 3 h, whereupon inserts were washed in PBS and immersed in SYTO 16 green fluorescent nucleic acid stain (Life Technologies, Carlsbad, CA). Cells seeded onto inserts but not subjected to flow were used as growth rate controls. A Nikon Eclipse epifluorescence microscope was used to capture nine low magnification fields/insert and nuclei were counted in ImageJ. The average number of attached cells was then expressed as a percentage of the no-flow controls.
Measurement of cell motility
GBM cell motility was measured using a fluorescence bead phagokinetic assay  as previously described . Briefly, wells of a six-well dish were coated with poly-D-lysine, whereupon 1 μM diameter fluorescent polystyrene microspheres (ThermoFisher Scientific, Grand Island, NY), adjusted to a concentration of 0.018% v/v in PBS were added and allowed to adhere to the poly-lysine for 2 h. Cells were plated in complete tissue culture medium (TCM) at a cell/area density of 4 cells/mm2. Experiments were performed either in DMSO or in 1 μm PD0325901. Experiments were also performed with PD0325901-treated cells incubated in hFn 7.1, a mouse monoclonal anti-human fibronectin antibody, or with non-specific mouse IgG. Motile cells phagocytose beads as they move leaving behind non-fluorescent tracks. Cleared area was quantified in ImageJ.
Measurement of aggregate dispersal velocity
50–100 μm diameter aggregates of DMSO or PD0325901-treated GBM-1-4 were deposited into 12-well tissue culture plates containing 2mls of pre-warmed TCM. Plates were incubated for eight h. Images were captured for each aggregate every hour and diameter at each time point was measured. Dispersal velocity (DV) was represented by the slope as determined by linear regression analysis for change of diameter as a function of time. Only regression lines with r2 values of 0.95 and greater were used to calculate DV for each GBM line. Data were normalized with initial aggregate diameter. Twelve aggregates were used to generate an average DV for each GBM line.
Measurement of z-axis dispersal distance by confocal microscopy
Dispersal of GBM cells through a NHA-seeded porous filter was measured as previously described . Two-hundred μm thick, cross-linked polystyrene scaffolds (Alvetex, Reinnervate, Durham, UK) with tunnel diameters of 8–13 μm were seeded with 1x106 NHA cells in 100 μL of tissue culture medium. After 60 min to allow NHA cells to adhere, scaffolds were placed in 12-well plates and incubated in 4mls of TCM for 48 h to permit incorporation of NHA cells throughout the scaffold. After 48 h, GBM cells that had been transfected with BacMam 2.0 GFPT (Life Technologies, Long Island, NY) were deposited onto each scaffold in a small volume of medium. Scaffolds were incubated for 48 h to allow time for tumor cells to infiltrate and disperse. To image dispersed cells, a Yokogawa CSU-X1 spinning disk confocal microscope with MetaMorph software was used to generate z-stacks of images taken at 1 μm intervals. Differential interference contrast microscopy was used to identify the z = 0 starting point for each z-stack. The z-axis position of each cell within each tissue-scaffold was scored. Within any given scaffold the mean average z-axis cell position from 5– 6 z-stacks was measured and recorded.
Measurement of cell growth in conventional 2D culture and in 3D spheroids
For measurement of growth in conventional 2D cultures, cells were plated at a concentration of 5x104 cells/ml in wells of a 6-well dish in complete medium. Total and live cell counts were performed once/day for 4 days using a BioRad TC10 automated cell counter. For measurement of growth rate by 3D spheroids, aggregates were generated using the hanging drop method . Single aggregates were plated onto wells of an agarose-coated 6-well dish. Agarose prevented aggregates from adhering to the bottom of the dish. The area of each aggregate was measured once/day for nine days. Growth rate was determined by plotting aggregate area as a function of time. Regression analysis was performed to calculate growth rates of 3D spheroids .
Effects of PD0325901 on FNMA, actin organization and pFAK localization in primary GBM cells
Studies have previously demonstrated a growth-inhibitory role for PD0325901 in GBM . Here, we explore another potential role as a suppressor of GBM dispersal. We first confirmed that the primary lines used in this study are sensitive to drug treatment. Figure 1a shows that PD0325901 treatment down-regulates p-ERK, the downstream effector of MEK, in all 4 primary GBM cell lines. Unlike Dex, PD0325901 did not induce FNMA (Fig. 1c) relative to DMSO controls (Fig. 1b). Rather, treatment resulted in a remarkable change in cell shape, treated cells (Fig. 1e) becoming flatter and larger than those treated with DMSO (Fig. 1d). PD0325901 treatment also gave rise to the organization of actin into stress fibers when cells were grown as conventional 2D culture (Fig. 1d, e), and a shift in actin organization from cortical to stress fibers when cells were incubated as 3D hanging drops (Fig. 1h, i). Moreover, PD0325901 treatment resulted in the localization of p-FAK at sites of cell-ECM attachment (Fig. 1g). These results indicate that PD0325901 treatment activates mechanisms involved in regulating cell motility and mechanical properties of single cells or cellular aggregates.
The effects of PD0325901 on spheroid mechanical properties are fibronectin dependent
We first generated measurements of aggregate cohesion for GBM-1-4 treated in either DMSO or PD0325901, and confirmed that the cohesion measured was reflective of a true tissue surface tension (Table 1). We demonstrated that all GBM samples exhibited the defining characteristics of liquid-like behavior: (1) they display a constant surface tension when subjected to two different degrees of compression. Accordingly, the means of σ1 and σ2 when compared by a paired t-test are not significantly different, (2) the ratio of σ2/σ1 approaches 1 and is less than the ratio of the applied force at each successive compression (F2/F1). Table 1 shows that for all lines, a t-test comparing the ratios of σ2/σ1 to F2/F1 resulted in a p < 0.0001, indicating that the ratio of σ2/σ1 was significantly different than that of F2/F1, and 3) the surface tension of the aggregates is independent of aggregate volume. For the 4 GBM lines, combined aggregate volumes were plotted as a function of surface tension. Linear regression analysis yielded correlation coefficients, r2, of 0.031 and 0.071 for DMSO and PD0325901 treated aggregates, respectively, indicating that surface tension is independent of volume (Additional file 1: Figure S2). Figure 2a shows that PD0325901 treatment did not have an effect on aggregate surface tension. Surprisingly, however, generation of 3D spheroids in the presence of 300 μg/ml of serum fibronectin (sFn) resulted in a significant increase in aggregate cohesion (Fig. 2b), suggesting that the effects of PD0325901 may be through enhancement of α5β1 integrin-fibronectin interaction. Since actin is a fundamental mediator of cell and tissue mechanics, we reasoned that PD0325901 mediated changes in actin reorganization should result in a change in aggregate stiffness and viscosity. Interestingly, for aggregates generated in 30 μg/ml sFn (30 sFn), PD0325901 treatment slightly increased stiffness (Fig. 2c) but had no effect on viscosity (Fig. 2d). However, when aggregates were generated in the presence of 300 μg/ml sFn, both stiffness (Fig. 2c) and viscosity (2D) markedly increased. This suggests that fibronectin is an absolute requirement for PD0325901 to alter mechanical properties.
PD0325901 increases resistance to shear-stress induced detachment, decreases cell motility and reduces dispersal velocity
The effects of PD0325901 on cell shape, actin reorganization and aggregate viscoelasticity translate to significant changes in tumor cell behavior. Notably, PD0325901 treatment rendered GBM cells more resistant to shear-induced detachment (Fig. 3a), suggesting a stabilization of cell-ECM adhesion and a decrease in area cleared by motile cells in a phagokinetic microbead assay. For all lines, cleared area was reduced approximately 3-fold in response to PD0325901 treatment, indicating a significant decrease in cell motility. When experiments were performed in TCM containing 5 μg/ml mouse monoclonal anti-human fibronectin antibody, the motility of PD0325901-treated cells was restored to levels comparable to those of DMSO controls (Fig. 3b). This effect was not observed when a non-specific mouse IgG was used (Additional file 1: Figure S4). These results indicate that the principal mechanism of PD0325901-mediated decrease in motility is α5β1 integrin-fibronectin dependent. Collectively, the observed increase in attachment strength to substrate and decreased motility gave rise to a significant overall decrease in aggregate dispersal velocity. Figure 3c shows that spheroids of GBM cells differ in baseline dispersal velocities and that PD0325901 treatment reduces DV relative to DMSO controls.
PD0325901 significantly alters pattern of dispersal and z-axis penetration
Treatment with the MEK inhibitor also resulted in a change in the pattern of dispersal. Whereas, the advancing edge of DMSO-treated aggregates dispersed as single cells (Fig. 4a, c), the leading edge of PD0325901-treated aggregates advanced as a sheet (Fig. 4b, d). Moreover, actin in advancing cells of DMSO-treated aggregates appeared to be cortical (Fig. 4b), whereas in treated aggregates, actin was arranged in stress fibers (Fig. 4d). This change in spreading behavior is likely associated with reduced cell motility, causing cells escaping the aggregate mass to accumulate behind the advancing front. PD0325901 treatment also resulted in a significant reduction in z-axis dispersal for three of the four lines (Fig. 4e). The z-axis dispersal distance of PD0325901-treated GBM-1 and GBM-2 cells was approximately 2-fold less than that of the vehicle controls. GBM-3 cells responded more actively, their z-axis dispersal distance becoming reduced approximately 13-fold relative to controls.
PD0325901 reduces growth rates of conventional 2D cultures and 3D spheroids of GBM cells
Previous studies demonstrated that the growth rate of various immortalized GBM cell lines was markedly reduced by PD0325901 . We tested our primary GBM lines to determine whether treatment had a similar effect when cells were grown as conventional 2D cultures and as spheroids. Figure 5 (a, b) shows that PD0325901 significantly decreases the growth rate of conventional 2D cultures of GBM-1-4 as compared to DMSO controls. We then repeated the experiment using spheroids of GBM cells. Figure 5c-f shows that PD0325901 treatment significantly reduced the growth rate of GBM aggregates since the slope of the growth curves was significantly reduced by treatment relative to that of controls. Linear regression analysis of the 3D growth curves revealed a 2–11 fold reduction in growth rate when spheroids of GBM cells were treated with the drug. In fact, PD0325901 treated aggregates appeared to decrease in size over time. This suggests that cells are either dying and sloughing off the surface of the aggregate – this was not observed for aggregates incubated for 2 days (Additional file 1: Figure S3, panel a) or 4 days (Additional file 1: Figure S3, panel b) on agarose plates – or that aggregates became more compact over time. This appears to be the case inasmuch as PD0325901 treatment resulted in more compact aggregates (Additional file 1: Figure S3, Panel c). It is likely that the observed compaction was due to overall contraction of cell size.
Therapies aimed at containing tumor cell dispersal could provide a powerful path towards extending the time of disease-free and overall survival of glioblastoma patients. Identifying drugs that can target molecular pathways involved in dispersal would provide valuable insight towards this goal. Our previous studies showed that Dexamethasone, an FDA approved drug to treat tumor-related edema in GBM, can also decrease in vitro and ex vivo dispersal of primary human GBM cells. It does so by activating α5β1 integrin and subsequent restoration of FNMA and re-organization of cortical actin into stress fibers. In turn, these changes engender an increase in the strength of intercellular cohesion, increased attachment of tumor cells to substrate, and reduced cell motility. The net effect is an overall reduction in dispersal [1, 27]. The effects of Dex, however, are pleiotropic and the drug likely targets many pathways, which in part may explain the many side-effects associated with Dex treatment. Identifying drugs that are more specific in their targeting of dispersal-related pathways is therefore important.
In this study, we explore whether inhibition of the MAPK/ERK pathway, a critical regulator of processes underlying invasion and metastasis , could have similar effects on GBM dispersal. We tested the effects of the MEK inhibitor, PD0325901, on 4 primary GBM cell lines that were previously used to assess the effects of Dex on dispersal [1, 21]. Studies have shown that certain GBM lines do not respond to MEK inhibitors . We therefore assessed whether our lines are responsive to PD0325901 by determining whether treatment results in a decrease in the levels of phospho-ERK. All 4 lines responded to the drug. We previously established that the cell lines were all deficient in their capacity for FNMA . In contrast to Dex, treatment with PD0325901 did not result in a significant increase in FNMA. However, treatment with the MEK inhibitor resulted in a remarkable change in cell shape and in the reorganization of actin from cortical into stress fibers. This was particularly evident when actin was visualized in 3D spheroids. Given that the actin cytoskeleton is a fundamental mediator of cell and tissue stiffness , we posited that a shift in actin organization would correspond to a change in tissue stiffness.
Stiffening of the ECM is considered to be a hallmark of fibrotic lesions and has been demonstrated to modulate cell invasion and migration . The current study focused on whether aggregate stiffness and viscosity could modulate dispersal. We quantified stiffness and viscosity using methods based on ellipsoid relaxation, specifically after the deforming external force is removed [31, 32]. The aggregate was modeled as a Kelvin-Voigt viscoelastic body [33, 34]. Unexpectedly, PD0325901 treatment only resulted in a modest increase in aggregate stiffness but not of viscosity. However, when aggregates were generated in higher concentrations of fibronectin, both stiffness and viscosity increased significantly. This is important for several reasons. First, the fibronectin gene has been shown to be up-regulated in GBM . Accordingly, tumors able to respond to PD0325901 and in the presence of high concentrations of fibronectin, could, in principle, become stiffer and more viscous. Stiffer tumors have previously been shown to be less invasive and to grow more slowly . Few studies have addressed the issue of tumor viscosity and those that have focus on applications of magnetic resonance elastography in liver tumors where fibrosis is a key parameter. In those studies, tumor viscosity appeared to be higher in malignant tumors . In GBM, however, fibrosis is not typically observed. In GBM spheroids, the increase in viscosity in response to PD0325901 treatment was likely due to higher binding energy between the activated α5β1 integrin and fibronectin. This would effectively increase the friction between cells and the ECM. This increase in friction could significantly reduce the capacity for dispersal of tumor cells from the primary mass.
Treatment also resulted in the localization of p-FAK at sites of cell-substrate attachment. This is consistent with the observed resistance to flow-induced substrate detachment of GBM cells, and to decreased motility. Since cells require intermediate levels of cell-ECM adhesion to be optimally motile , an increase in the strength of cell-ECM adhesion past this point might stabilize adhesion to substrate to a point that significantly reduces cell movement, and consequently, dispersal. Decreased motility also appears to be associated with a significant decrease in dispersal velocity of GBM aggregates. Since PD0325901 treatment did not restore FNMA, it is likely that decreased motility rather than increased cohesion is the physical mechanism that restrains the detachment of tumor cells from the mass. Indeed, cells at the leading edge of treated aggregates appear to attach tightly to substrate causing cells behind them to pile up, again pointing to reduced motility as the primary restraint for detachment. For three of the four primary GBM lines, PD0325901 also significantly reduced the ability of single GBM cells to disperse through an astrocyte-seeded scaffold. It is not possible to differentiate between the effects of PD0325901 on decreased motility and ability to disperse through the scaffold, however, it is possible that on a single cell level, the re-organization of actin into stress fibers may have effectively rendered cells less compliant and inhibited their capacity to sufficiently deform and squeeze through pores established by the physical environment established by the scaffold. It is important to note that for GBM-4, treatment did not reduce z-axis dispersal. It is possible that in this line, compliance was not effected by treatment, thus allowing cells to penetrate into the scaffold.
Lastly, MEK inhibitor treatment also appears to significantly reduce growth rate of these primary GBM lines in both conventional 2D and in 3D cultures. Other studies have demonstrated in vivo efficacy of PD0325901 in reducing tumor growth in preclinical orthotopic models of glioblastoma . Our study provides compelling evidence that PD0325901 can also reduce dispersal. Growth and dispersal contribute significantly to recurrence. Accordingly, the drug has the potential to significantly delay the onset of recurrence in GBM.
Identifying agents that can contain the primary or recurrent tumor could significantly improve targeted delivery of chemotherapeutic agents and increase the likelihood of total surgical resection. We have previously identified Dexamethasone (Dex) as a potential candidate to reduce dispersal of GBM . Interestingly, the doses required to elicit a dispersal inhibitory response are significantly lower than those typically used to reduce edema . Clinically, MEK inhibitors are generally well tolerated. Commonly occurring toxicities include rash, diarrhea, fatigue, peripheral oedema and acneiform dermatitis. Life-threatening toxicities associated with MEKi are extremely rare. Long-term use is possible providing that adverse events are monitored and dose or treatment schedules are modified, as required . The measureable outcome for MEK inhibitor studies focus on their ability to reduce tumor size. Here, we show an added benefit of one MEK inhibitor as a potential deterrent of tumor cell dispersal. Whereas Dexamethasone readily crosses the blood–brain barrier, some MEK inhibitors, including trametinib, have demonstrated limited brain distribution due to association with the P-glycoprotein efflux transporters found at the blood–brain barrier . Perhaps a strategy in which MEK inhibitors are used as interstitial chemotherapy, followed by continued administration of low-dose Dex, could significantly improve prognosis of this devastating disease.
This study demonstrates that it is possible to impede dispersal of GBM by inhibiting the MAPK/ERK pathway using the MEK inhibitor PD0325901. To our knowledge, this is the first demonstration that the drug can also impede GBM dispersal. Containing the primary or recurrent tumor by interstitial administration of MEK inhibitors could significantly improve delivery of chemotherapeutic agents and increase the likelihood of total surgical resection. This could significantly extend the time of disease-free and overall survival of glioblastoma patients.
Astrocyte growth medium
Electron multiplying charge coupled device
Eagle’s Minimal Essential Medium
Fetal calf serum
Fibronectin matrix assembly
mitogen activated protein kinase/extracellular signal regulated kinase
Normal human astrocytes
polyacrylamide gel electrophoresis
Phosphate buffered saline
sodium dodecyl sulphate
Tissue surface tensiometry
Shannon S, Vaca C, Jia D, Entersz I, Schaer A, Carcione J, Weaver M, Avidar Y, Pettit R, Nair M, et al. Dexamethasone-mediated activation of fibronectin matrix assembly reduces dispersal of primary human glioblastoma cells. PLoS One. 2015;10(8):e0135951.
Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R, Borges H, Neto VM. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011;89(15–16):532–9.
Burden-Gulley SM, Qutaish MQ, Sullivant KE, Tan M, Craig SE, Basilion JP, Lu ZR, Wilson DL, Brady-Kalnay SM. Single cell molecular recognition of migrating and invading tumor cells using a targeted fluorescent probe to receptor PTPmu. Int J Cancer. 2013;132(7):1624–32.
Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009;28(1–2):113–27.
Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res. 1995;55(21):5043–8.
Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, Bussey KJ, Nishizuka S, Ikediobi O, Pommier YG, et al. Multifactorial regulation of E-cadherin expression: an integrative study. Mol Cancer Ther. 2010;9(1):1–16.
Montenegro RC, de Vasconcellos MC, Barbosa Gdos S, Burbano RM, Souza LG, Lemos TL, Costa-Lotufo LV, de Moraes MO. A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling. Toxicol In Vitro. 2013;27(7):2076–83.
Asano K, Duntsch CD, Zhou Q, Weimar JD, Bordelon D, Robertson JH, Pourmotabbed T. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J Neurooncol. 2004;70(1):3–15.
Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59(6):1304–12. discussion 1312.
Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61(2):198–223.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of Dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol. 2014;21(3):e493–503.
LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6):1924–37.
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782–9.
Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482–9.
Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456–62.
Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia. 2009;11(8):720–31.
El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model Mech. 2015;8(1):45–56.
Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos. 2014;42(8):1292–300.
See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 2012;72(13):3350–9.
Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE. Radiosensitization of primary human glioblastoma stem-like cells with Low-dose AKT inhibition. Mol Cancer Ther. 2015;14(5):1171–80.
Foty RA, Forgacs G, Pfleger CM, Steinberg MS. Liquid properties of embryonic tissues: measurement of interfacial tensions. Phys Rev Lett. 1994;72(14):2298–301.
Foty RA, Pfleger CM, Forgacs G, Steinberg MS. Surface tensions of embryonic tissues predict their mutual envelopment behavior. Development. 1996;122(5):1611–20.
Foty RA, Steinberg MS. The differential adhesion hypothesis: a direct evaluation. Dev Biol. 2005;278(1):255–63.
Forgacs G, Foty RA, Shafrir Y, Steinberg MS. Viscoelastic properties of living embryonic tissues: a quantitative study. Biophys J. 1998;74(5):2227–34.
Windler-Hart SL, Chen KY, Chenn A. A cell behavior screen: identification, sorting, and enrichment of cells based on motility. BMC Cell Biol. 2005;6(1):14.
Sabari J, Lax D, Connors D, Brotman I, Mindrebo E, Butler C, Entersz I, Jia D, Foty RA. Fibronectin matrix assembly suppresses dispersal of glioblastoma cells. PLoS One. 2011;6(9):e24810.
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.
Wakatsuki T, Schwab B, Thompson NC, Elson EL. Effects of cytochalasin D and latrunculin B on mechanical properties of cells. J Cell Sci. 2001;114(Pt 5):1025–36.
Kai F, Laklai H, Weaver VM: Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends Cell Biol. 2016;26(7):486–97.
Zhang J, Zahn JD, Lin H. Transient solution for droplet deformation under electric fields. Phys Rev E Stat Nonlin Soft Matter Phys. 2013;87(4):043008.
Yu M, Lira RB, Riske KA, Dimova R, Lin H. Ellipsoidal relaxation of deformed vesicles. Phys Rev Lett. 2015;115(12):128303.
Darby R. Viscoelastic fluids, and introduction to their properties and behaviour. New York-Basel: Marcel Decker; 1976.
Meyers M, Chawla K. Mechanical behavior of materials. Cambridge: Cambridge University Press; 2009.
Serres E, Debarbieux F, Stanchi F, Maggiorella L, Grall D, Turchi L, Burel-Vandenbos F, Figarella-Branger D, Virolle T, Rougon G, et al. Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene. 2014;33(26):3451–62.
Fenner J, Stacer AC, Winterroth F, Johnson TD, Luker KE, Luker GD. Macroscopic stiffness of breast tumors predicts metastasis. Sci Rep. 2014;4:5512.
Garteiser P, Doblas S, Daire JL, Wagner M, Leitao H, Vilgrain V, Sinkus R, Van Beers BE. MR elastography of liver tumours: value of viscoelastic properties for tumour characterisation. Eur Radiol. 2012;22(10):2169–77.
DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA. Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol. 1993;122(3):729–37.
Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol. 2015;7(2):122–36.
The authors gratefully acknowledge the efforts of Dr. Joseph Kramer, Director, Confocal Imaging Facility, Rutgers-Robert Wood Johnson Medical School, for assistance in image acquisition and analysis.
SS was supported by an NIH Institutional Research and Academic Career Development Award K-12 GM093854. MY received funding from the NSF-CMMI. LL was supported by grants from NSF-DMS and from the AFOSR. The study was also supported from research funds from the Department of Surgery-Robert Wood Johnson Medical School to RAF.
Availability of data and materials
All data supporting conclusions are presented in the paper and additional supporting files, Supplemental Information (Supplemental Information file.docx). Key data sets analysed during the current study are available in the Figshare repository, https://figshare.com/s/c21a883c899aedf37a69 and https://figshare.com/s/d79e86c1726052c61dc5.
SS performed and analyzed the dispersal velocity and aggregate spreading assays. DJ performed the immunoblot and immunofluorescence assays. IE generated and analyzed the cell attachment data. PB, CC and JC performed the tissue surface tensiometry assays for measurement of aggregate cohesion and analyzed the data. AM performed the experiments for measurement of aggregate stiffness and viscosity. MY designed the in-house image capture and analysis algorithm and also analyzed the shape relaxation images for extraction of the stiffness and viscosity data. CV conceived, performed and analyzed the cell motility assay. MW generated and analyzed the ex vivo dispersal data. DS, JDZ, LL and HL conceived, designed, and mathematically solved the solution for extraction of stiffness and viscosity. They also supervised the project at the Departments of Biomedical Engineering (DS, JDZ) and Mechanical and Aerospace Engineering (LL, HL), respectively. RAF conceived the study, supervised the overall project, statistically analyzed the data, generated the figures, interpreted the results, and wrote the manuscript. All authors reviewed and edited the manuscript for intellectual content and have approved the final version.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Tumor samples were obtained with approval of the Rutgers-Robert Wood Johnson Medical School Institutional Review Board under protocol #CINJ 001208. Samples were anonymized and the IRB waived the need for written consent. Cell lines GBM-1, GBM-2, GBM-3 and GBM-4 were developed directly from these tumor samples and are therefore covered under the same IRB protocol.